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Abstract
Background: Skin cancer is one of the most common cancers in the world. The increased incidence of skin cancer,
combined with limited health care resources and tight budgetary conditions, has increased the importance of
understanding the economic impact of skin cancer. This research estimates the economic cost of skin cancer in the
Australian state of New South Wales.
Method: An incidence based approach is used to estimate lifetime costs of skin cancer. Both direct and indirect
costs are considered - direct costs include resources associated with the management of skin cancer and indirect
costs refer to productivity costs associated with morbidity and premature mortality. Diagnosis of skin cancer was
determined according to ICD-10 codes using principal diagnosis. Linked administrative data and regression
modelling are used to calculate costs; presented as Australian dollars for the year 2010. The human capital
approach is used to value present and future productivity losses.
Results: The lifetime cost of the 150,000 incident cases of skin cancer diagnosed in NSW in 2010 is estimated at
$536 million ($44,796 per melanoma and $2459 per non-melanoma). Direct costs accounted for 72 % of costs
($10,230 per melanoma and $2336 per non-melanoma) and indirect costs accounted for 28 % of costs ($34,567
per melanoma and $123 per non-melanoma). Direct costs are, on average, higher for females than males with
indirect costs, on average, higher for males than females.
Conclusion: This research provides new evidence on the economic cost of skin cancer and provides policy
makers with information of the potential monetary savings that may arise from efforts to reduce the incidence
of skin cancer.
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Background
Skin cancer is one of the most common cancers in the
world [1–4]. The majority of skin cancers develop from
exposure to ultraviolet radiation (UVR), particularly
from sun exposure. The highest incidence rates of skin
cancer worldwide are in Australia and New Zealand,
where two out of every three people are likely to be di-
agnosed in their lifetime [5].
Basal cell carcinoma (BCC) is the most common form of
skin cancer followed by squamous cell carcinoma (SCC)
[1, 2]. Together, BCC and SCC make up the majority of
non-melanoma skin cancers (NMSC). Malignant melan-
oma accounts for less than five percent of skin cancer
cases, yet it represents the vast majority of skin cancer
deaths in Australia [6]. The incidence of skin cancer is in-
creasing in Australia, and the incidence rate is greater than
breast, prostate, lung and colon cancers combined. In
terms of prevalence, more people have been diagnosed
with skin cancer than all other cancers combined over the
past three decades [7].
The management of skin cancer generally involves
diagnosis, treatment and follow-up. Melanoma, SCC and
BCC are typically detected opportunistically during spe-
cific skin examinations by skin cancer specialists or der-
matologists, or during general health checks by a general
practitioner. In Australia, the standard treatment for
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primary melanoma is wide local excision of the skin and
subcutaneous tissues around the melanoma. The aim is
complete surgical excision of all in situ and invasive mel-
anoma components, confirmed by comprehensive histo-
logical examination [8]. Surgery is the prime treatment
for NMSC: more than 70 % of the BCC lesions recorded
in the 2002 National survey were surgically excised [9].
For BCCs not surgically excised, cryotherapy was more
commonly used for upper and lower limb lesions than fa-
cial lesions, and 10 % of BCCs were treated with curettage
and diathermy. Anecdotal evidence suggests that non-
surgical treatment has increased since 2002 for superficial
BCC with imiquimod in particular. The majority of SCC
lesions, regardless of body site, were treated by surgical
excision [9, 10]. Confirmation of complete removal of le-
sions is an essential part of management [10].
The post-treatment follow-up regimen is relatively in-
tensive in Australia with clinical guidelines recommend-
ing post melanoma treatment follow-up visits every six-
months for five years for patients with stage I disease,
three-monthly or four-monthly for five years for patients
with stage II or III disease, and yearly thereafter for all
patients [8]. NMSC recommendations for follow-up have
yet to be established for the detection of further primary
tumours, however, some suggestions have been made
that six-monthly follow-up for two years may assist in
early detection of new primary tumours or of metastatic
disease [10].
The incidence of skin cancer increases with age [11, 12].
With most western countries experiencing a demographic
transition towards an older cohort, including Australia,
the incidence and prevalence of skin cancer is rising, along
with the consequential economic impact, even though
incidence in younger age groups (i.e., less than 55 years) is
stabilising [12–14].
The economic impact of skin cancer can be considered
as a combination of direct and indirect costs. Direct
costs include the management of skin cancer from diag-
nosis, treatment to follow-up, and refer to the utilisation
of health care resources such as hospital, medical and
allied health care services. Indirect costs reflect the lost
productivity resulting from an individual’s inability to
work (morbidity costs such as sick leave and early retire-
ment) and premature mortality (defined as death before
the age of 65 years, the upper limit of the working age in
Australia).
The increased incidence and prevalence of skin can-
cers, combined with the current fiscal environment of
limited health care resources and tight budgetary condi-
tions, has increased the importance of understanding
the economic impact of skin cancer. From a policy view-
point, it is important to understand the resource re-
quirements of the current skin cancer burden and the
efficiency of competing strategies that are most likely to
lower the incidence of skin cancer and, therefore, reduce
its burden. Although several international studies have ex-
amined the direct cost of skin cancer treatment [15–26],
and two have examined indirect costs [27, 28]; our review
of the literature found only four studies that had com-
bined both direct and indirect costs in the same analysis
[29–32]. Morris et al. [31] estimated the cost of skin can-
cer in England in 2002 at £240 million, equivalent to
£4249 per case (AUD$12,567 in 2010 prices). Tinghog et
al. [29] estimated the cost of melanoma and NMSC in
Sweden in 2005 at €116 million, equivalent to €3019 per
case (AUD$5366 in 2010 prices). Eriksson and Tinghog
[32] updated the 2005 Swedish estimate and reported a
combined cost of melanoma and NMSC at €136 million.
The authors did not report incidence rates or average cost
per case, but noted that costs had risen by 14 % after
adjusting for inflation since 1995 [32]. O’Dea estimated
the cost of skin cancer in New Zealand in 2007 at
$NZ123.10 million, equivalent to $NZ1,785 per case
(AUD$1650 in 2010 prices) [30]. The general trend in
these country specific studies is higher direct costs for
NMSC (because of their relatively high prevalence) and
higher indirect costs for melanoma (because of its rela-
tively greater severity of illness in those of working
age). Although the proportion of costs attributable to
indirect costs in all three studies to date appears com-
parable at around 54 %, total costs appear to vary
widely partly due to methodological differences.
New South Wales (NSW) is Australia’s most populated
state with an estimated population of 7.29 million (34.5 %
of the population of Australia). One of the key objectives
of the skin cancer prevention strategy for NSW (2012–
2015) is to increase and utilise evidence to inform future
planning and development of skin cancer prevention strat-
egies with a priority on: increasing the adoption of UVR
protection behaviours; increasing shade provision; and im-
proving polices to increase protection from UVR across a
range of settings and life stages [33]. Although an under-
standing of the magnitude of the economic burden of skin
cancer in NSW is important given its high incidence, there
is currently a clear lack of such evidence. The objective of
this study is to estimate the economic cost (both direct
and indirect) of skin cancer in NSW. A lifetime approach
is adopted, which estimates costs over the management of
skin cancer through diagnosis, treatment and follow-up.
Methods
Ethics
Ethics clearance was obtained from the New South
Wales Ministry of Health (2012/09/417).
Economic approach
Economic costs may be estimated using either the
prevalence or incidence-based approach to costing. A
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prevalence-based approach provides estimates of costs
for the total population for one year, or costs accumu-
lated over a longer time horizon [34]. An incidence-
based approach follows a disease cohort for the duration
of the disease and estimates discounted costs [34], it is the
most commonly used method as it allows policy makers
to understand the potential impact of reducing the inci-
dence of a disease by adopting cost-effective strategies.
This analysis uses the incidence based approach to esti-
mate lifetime economic costs. This lifetime perspective
reflects the recommended clinical management of skin
cancer in Australia [8, 10], managing melanoma and
NMSC for five and two years respectively, post diagnosis.
Total economic costs in 2010 are derived by multiplying
the number of incident cases in 2010 by estimates of the
average lifetime direct and indirect costs.
Epidemiological data
In Australia, melanoma is notifiable to cancer registries.
To estimate the incidence of melanoma by age and gen-
der, data were obtained from the NSW Central Cancer
Registry (CCR) which at the time of writing was avail-
able up to 2008 [35]. These data were combined with
Australian Bureau of Statistics (ABS) estimates of the
resident NSW population in 2010 [36].
Unlike melanoma and other invasive cancers, NMSC
is not notifiable by law to cancer registries in Australia,
despite being the most commonly diagnosed cancer.
Consequently, rates of NMSC have been estimated from
population surveys [5, 9, 37, 38]. The most recent survey
was conducted by the National Cancer Control Initiative
(NCCI) in 2002 [9]. To estimate the incidence of NMSC
by age and gender, data from the NCCI survey were
combined with ABS estimates of the resident NSW
population in 2010 [36].
Calculating direct costs of skin cancer
Data sources
A range of linked data sources (Table 1) were utilised to
determine direct costs: the 45 and Up study (45&Up)
[39]; NSW CCR [35]; NSW admitted patient data collec-
tion (APDC) [40]; ABS mortality [6]; Pharmaceutical
Benefit Schedule (PBS) [41]; Medicare Benefit Schedule
(MBS) [42]; and, the NSW Registry of Births, Deaths
and Marriages (RBDM) [43].
Diagnosis of skin cancer
Diagnosis of melanoma (both in-situ and invasive) was
determined by the principal diagnoses codes in the
Australian modified International Statistical Classifica-
tion of Diseases and related health problems, 10th revi-
sion (ICD-10-AM), specifically codes C43 (malignant
melanoma of skin) and D03 (melanoma in situ) [44].
Diagnosis of NMSC was identified using codes C44
(malignant neoplasm of skin) and D04 (carcinoma in
situ of skin). Diagnosis was also derived from MBS and
PBS utilisation and self-report data from the 45&Up
study.
Analysis criteria
Costs were calculated for, and compared across, three
diagnostic groups: melanoma; NMSC; and, neither mel-
anoma or NMSC. Participants self-reported having ei-
ther melanoma or NMSC in the 45&Up survey by their
responses to the following two questions: “Has a doctor
EVER told you that you have melanoma?” “Has a doctor
EVER told you that you have skin cancer (not melan-
oma)?” Self-reported responses were validated by linked
records in the CCR, APDC and MBS. Participants with-
out CCR, APDC or MBS records were classified as diag-
nosis uncertain if their evidence of diagnosis - for either
skin cancer - was only self-identification in the 45&Up
survey or only relevant MBS records. This group was
omitted from analysis due to the ambiguity of their sta-
tus. The group ‘neither melanoma or NMSC’ had no
data relevant to melanoma or NMSC diagnosis and is
used as the control group in the regression analysis.
Direct costs
Cost groupings were derived from the following sources
(data periods appear in brackets):
1. Primary care medical costs: MBS (04/08/2003 to 31/
12/2011)
2. Pharmaceutical costs: PBS (01/06/2004 to 31/12/
2011)
3. Hospital costs: APDC (01/07/2000 to 31/12/2011)
Variations in data coverage reflect the nature of linking
multiple patient-level data sources. To ensure consistency,
data from these files were analysed only for their overlap
period, 01/06/2004 to 31/12/2011. MBS, PBS and APDC
cost estimates were converted to 2010 prices using appro-
priate price inflators [45].
Estimation of lifetime direct costs used longitudinal
methods to estimate average costs (MBS, PBS and
APDC), for each diagnosis group, for each calendar year
since diagnosis - for 5 years post diagnosis for melanoma
and 2 years post diagnosis for NMSC. A cost per annum
from year of diagnosis reflects that any cost difference
between those with and without a diagnosis is likely to
be most pronounced in the first years of diagnosis. Re-
gression analysis is used to estimate the effect on the
cost associated with a diagnosis of either melanoma or
NMSC, compared to the control group, i.e., those with-
out a diagnosis. The dependent variable is the average
annual cost for the year as identified as the year from
diagnosis. The covariates included in this model are
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listed in Table 2 and include the years from diagnosis as
an explanatory variable.
The analysis can be represented by the following
equation:
ALC ¼ NPV CMi½   IM þ NPV CNMSCi½ 
 INMSC
Where:
 ALC = average lifetime cost of skin cancers
diagnosed in 2010;
○ NPV = net present value
○ CMi = average annual cost per case of
melanoma relative to year of diagnosis i;
○ CNMSCi = average annual cost per case of
NMSC relative to year of diagnosis i;
○ IM = incidence of melanoma in 2010;
○ INMSC = incidence of NMSC in 2010.
From each data source (MBS, PBS, APDC) cost data
was obtained for each calendar year of the collection
period (2004–2011). The data sets were merged on per-
son number and year. The dataset had one record for
each participant for each calendar year of the collection
period. Records contained fields for calendar year MBS,
PBS, APDC costs and, for participants with skin can-
cer, years since year of diagnosis. Costs are inclusive
of patient and government contributions. Participants
who died during the collection period only had re-
cords for the calendar years in which they were alive.
Mortality information was sourced from ABS mortal-
ity [6] and the NSW Registry of Births, Deaths and
Marriages (RBDM) [43].
Table 1 Summary of available administrative data
Data source Abbreviation Overview of data collected Period of data collection Number of
possible records
45 and Up survey 45& Up The 45&Up survey is of individuals aged 45 and over in
NSW - the survey includes information on health, lifestyle






CCR The CCR includes records for all reported cancer cases
from NSW Central Cancer Registry. The CCR records
include a range of demographic data items (e.g. date of birth,
residential address), staging information, year of diagnosis,
plus diagnostic information (e.g. reason for death, Morphology
code, Topography Code etc.). The CCR cohort comprises
individuals registered on NSW CCR and diagnosed with








APDC The APDC includes all hospital separations of skin cancer
(melanoma, melanoma in situ, non-melanoma) and/or a
precursor of skin cancer (sunburn, actinic keratosis or
melanocytic naevi) in NSW during the period July 2000-Dec 2011
from all NSW public and private hospitals and day procedure
centres. APDC records include a range of demographic data
items, administrative items (e.g. admission and separation dates)
and diagnostic information (e.g. reason for admission, significant
co-morbidities and complications and procedures performed
during the admission).










The ABS cohort includes all cases where skin cancer is
recorded as the primary or contributing cause of death.
Cause of death is coded according to the International








PBS The PBS is administered by Medicare Australia and includes
all processing claims and payment benefits for pharmaceutical
medications for most medical conditions. This source contains





MBS The MBS is a listing of medical and hospital services that are
subsidised by the Australian government. The MBS includes
primary care practitioner and specialist consultations and exclude
ambulance and allied health services. This source contains costs









The Registrar of the NSW Registry of Births, Deaths and Marriages
(RBDM) is a registry all births and deaths in NSW
RBDM records linked to
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Regression modelling for average lifetime direct costs
used General Estimating Equations (GEE) analysis. Given
a priori evidence of skewed cost data (i.e., large number of
zero or small cost observations with a small number of
observations with very large costs), GEEs were run with a
gamma family and log link. Standard diagnostic tests were
conducted (e.g. correlations between independent vari-
ables and comparisons of residuals and predicted values).
Robust variance estimators were included to ensure
more robust estimates of standard errors. Margins
(estimates) were derived for average treatment costs
for each year from diagnosis by each diagnosis status
(melanoma, NMSC) and compared to average annual
direct costs for people with no skin cancers. These
incremental results were then multiplied by skin can-
cer incidence figures to derive lifetime direct costs for
NSW in 2010.
All regressions were conducted with STATA 12 soft-
ware. Regression results are available from authors upon
request.
Calculating indirect costs of skin cancer
Indirect costs quantified in this analysis include morbid-
ity and premature mortality for those of working age.
Morbidity estimates
The Australian Burden of Disease study provide infor-
mation on total years lived with a disease and the loss of
health (referred to as a disability weight - DW) associ-
ated with that disease [46]. Disability weights are based
on a scale ranging from 0 to 1 where 0 represents per-
fect health and 1 represents death [46]. For skin cancer,
a range of DWs are used to reflect health states in rela-
tion to sequelae. Across the entire disease spectrum, the
Table 2 Variables used in costing analysis
Variables Sources Question/Variable Data
Format
Analysis summary
Medical Charges APDC Average costs per AR-DRGs (from government ‘Costs of Care’ reports Continuous
($)
Averages and totals across
diagnosis groups and periods
MBS Charges Continuous
($)
Averages and totals across
diagnosis groups and periods
PBS Gross Price Continuous
($)
Averages and totals across
diagnosis groups and periods
Diagnoses
Melanoma
CCR Inclusion in the CCR Inclusion
45& Up Question: ‘Has a doctor ever told you that you have melanoma’? Yes/No Proportions
MBS Relevant MBS Charges Continuous
($)
Averages and totals across
diagnosis groups and periods
APDC Relevant Primary Diagnoses items Continuous
($)
Averages and totals across
diagnosis groups and periods
Diagnosis NMSC 45& Up Question: ‘Has a doctor ever told you that you have skin cancer
(NMSC)’?
Yes/No Proportions
MBS Relevant MBS Charges Continuous
($)
Averages and totals across
diagnosis groups and periods
APDC Relevant Primary Diagnoses items Continuous
($)
Averages and totals across
diagnosis groups and periods
Diagnosis Calendar
Year (melanoma)
CCR Year of Diagnosis’ variable Year
APDC Date of Separation Year
45& Up Question: ‘At what age were you told you had melanoma?’ (Allows
calculation of year with variable ‘Year of Birth’)
Continuous Averages and totals across
diagnosis groups and periods
Diagnosis Calendar
Year (NMSC)
45& Up Question: ‘At what age were you told you had skin cancer (NMSC)’
(Allows calculation of year with variable ‘Year of Birth’)
Continuous Averages and totals across
diagnosis groups and periods
APDC Date of Separation Year




Year of Death RBDM Year of death variable Year Year
APDC NSW Admitted patient data collection; CCR NSW Central Cancer Registry; MBS Medicate Benefit Schedule; PBS Pharmaceutical Benefit Scheme; RBDM NSW
Registry of Births, Deaths and Marriages; 45&UP The 45 and Up study
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average DW is 0.19 and 0.06 for melanoma and NMSC,
respectively. An estimate of the average health years of
life lost due to skin cancer are used as a proxy for mor-
bidity costs in this analysis and are derived by dividing
total years lived with skin cancer with the relevant DW.
The human capital approach is used in this analysis to
value the loss of productive life. The approach equates the
value of a human life to the discounted market value of
the output produced by an individual over an expected
lifetime. In other words it uses forgone income to estimate
forgone productivity [34, 47]. The value of a healthy year
of life is equivalent to the average annual earnings in
NSW for 2010 - $61,105 for males and $42,238 for fe-
males [48]. A further adjustment is made to this value to
reflect the likelihood of being employed - 82 % in males
and 68 % in females [49].
Premature mortality
Premature mortality costs are derived by valuing poten-
tial years of life lost (PYLL) due to skin cancer before
the age of 65. The most comprehensive source of skin
cancer mortality data in NSW is provided by the ABS
[6]. Dividing ABS data on PYLL with number of deaths
provides an estimate of average years of life lost per
death.
ABS data does not, however, report age of death so an
alternate means was required to estimate average years
of life lost due to skin cancer before the age of 65. The
CCR provides individual level data on age at melanoma
diagnosis and age at death [35]. For melanoma, CCR
data suggest that 38 and 35 % of total years of life were
lost in those dying before the age of 65 years, for males
and females respectively. In the absence of similar CCR
data for NMSC, this proportion is applied to ABS data
on PYLL and deaths to estimate the average years of
productive life lost per incident case of skin cancer.
As above for morbidity, average annual earnings, ad-
justed for employment, is used as a proxy for the value
of a productive year. All future costs are converted to
present value using a 3 % discount rate.
Results
Epidemiology
Table 3 provides an overview of skin cancer epidemi-
ology in NSW. In 2010, there were an estimated 3797
new cases of melanoma (2295 male and 1502 female)
and 148,610 new cases of NMSC (86,812 male and
61,798 female). Equivalent age-standardised incidence
rates are, for melanoma, 65 and 42 per 100,000 males
and females, respectively; and, for NMSC, 2449 and
1716 per 100,000 males and females, respectively. For
melanoma, the average years of healthy life lost are 3.66
for males (equivalent to 254 days) and 1.77 years for fe-
males (equivalent to 123 days). For NMSC, the average
years of healthy life lost are 0.05 years for males (equiva-
lent to 16 days) and 0.02 years for females (equivalent to
6 days).
In 2010, 359 men and 155 women lost their lives to
melanoma corresponding to an age-standardised death
rate of 9.8 and 3.6 per 100,000 for males and females, re-
spectively. NMSC claimed the lives of 104 men and 41
females, corresponding to an age-standardised death rate
of 2.9 and 0.8 per 100,000 for males and females, re-
spectively. For melanoma, PYLL per death are 9.34 years
for males and 10.14 years for females. For NMSC, PYLL
per death are 5.44 years for males and 2.53 for females.
For those dying of melanoma before the age of 65 years
Table 3 Epidemiology of skin cancer in New South Wales, 2010
Melanoma NMSC
Males Females Males Females
Incidence
Incident cases 2295 1502 86,812a 61,798a
Incidence rate per 100,000 65 42 2449 1716
Morbidity
Total years lived with disease 19,332 7089 9933 2533
Average healthy years of life lost due to disease 3.66 1.77 0.05 0.02
Mortality
Deaths (2010) 359 155 104 41
Total years of life lost 3353 1571 566 104
Average years of life lost 9.34 10.14 5.44 2.53
Mortality before the age of 65 years
Average years of productive life lost 4.52 5.14 2.07 0.88
aNMSC is estimated from a 2002 NCCI report - the incident rate is assumed steady for 2010 and has not risen
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(i.e., 38 % males and 35 % of females), the average years
of productive life lost are 4.52 years for males and
5.14 years for females. For those dying of NMSC before
the age of 65 years (i.e., 38 % males and 35 % of fe-
males), the average years of productive life lost are
2.07 years for males and 0.88 years for females.
Economic cost of skin cancer
The lifetime economic cost of skin cancer cases in
NSW in 2010 is estimated at AUD$536 million or
AUD$3514 per incident case (Table 4). Each incident
melanoma case costs an average AUD$44,796 com-
pared with AUD$2459 per NMSC case. NMSC costs
account for 68 % (AUD$365 million) of total lifetime
economic costs. Direct lifetime costs are estimated at
AUD$386 million (AUD$2533 per case), with NMSC
representing 90 % of total direct costs - AUD$347 mil-
lion (AUD$2336 per case) and melanoma 10 % of total
direct costs - AUD$39 million (AUD$10,230 per case).
Indirect lifetime costs are estimated at AUD$150 million
(AUD$981 per case) with melanoma representing 88 % of
total indirect costs - AUD$131 million (AUD$34,567 per
case) and NMSC 12 % of total indirect costs - AUD$18
million (AUD$123 per case). Direct lifetime costs are, on
average, higher for females than males with indirect costs,
on average, higher for males than females.
Discussion
In conducting this study a range of data sources and
methods were used. As such, a number of potential
limitations and strengths of the analysis need to be
considered.
Limitations
First, while the CCR data informed the incidence of mel-
anoma in NSW, partial data sources were relied on to
develop an understanding of the incidence of NMSC.
These data sources are dated and may not reflect recent
changes in incidence of NMSC. Second, our analysis did
not consider the cost of skin cancer by stage of diagnosis,
type of treatment, treatment provider or socio-economic
status. Evidence suggests that there are variations in costs
across these categories [15–18]. In our study, although
CCR provided information on staging of disease at time of
diagnosis, no other data set had comparable data. Third,
the base year for the analysis is 2010. This year is appro-
priate given data availability but it is acknowledged that
skin cancer management may have changed over recent
years. Fourth, a limitation of productivity estimates is a
Table 4 Incident cases, direct cost, indirect cost and total cost of skin cancer in NSW, 2010a
Melanoma NMSC Total
Incident cases
Female 1502 61,798b 63,300
Males 2295 86,812b 89,106
Total 3797 148,610b 152,407
Direct costs
Females $16,349,530 $230,717,528 $247,067,059
Cost per female incident case $10,882 $3733 $3903
Males $22,494,516 $116,426,574 $138,921,090
Cost per male incident case $9803 $1341 $1559
Total $38,844,046 $347,144,102 $385,988,148
Cost per incident case $10,230 $2336 $2533
Indirect costs
Females $34,928,193 $2,259,156 $37,187,349
Cost per female incident case $23,249 $37 $587
Males $96,325,255 $16,016,487 $112,341,742
Cost per male incident case $41,977 $184 $1261
Total $131,253,448 $18,275,643 $149,529,091
Cost per incident case $34,567 $123 $981
Total costs $170,097,494 $365,419,746 $535,517,240
Cost per incident case $44,796 $2459 $3514
aAverage cost may not equate to total cost divided with cases due to rounding
bNMSC is estimated from a 2002 NCCI report - the incident rate is assumed steady for 2010 and has not risen
Doran et al. BMC Public Health  (2015) 15:952 Page 7 of 10
lack of complete Industry data. A recent study conducted
by Safe Work Australia on exposure to direct sunlight and
the provision of sun exposure controls in Australian work-
places, provides evidence that certain workers have a
higher likelihood of being exposed to direct sunlight [50].
Further, the report suggests that the provision of sun
protection (i.e. sunscreen, protective clothing, hats,
sunglasses and being able to reorganise work outside
peak UVR hours) was affected by worker employment
and demographic characteristics [50]. The lack of data
precludes a more robust assessment of Industry-related
costs due to skin cancer in this analysis. Fifth, the ana-
lysis did not value the contribution made by carers. A
report by Access Economics for Carer’s Australia exam-
ined and valued the amount of informal care being pro-
vided in Australia [51]. The report suggests that in
2010, over 1 in 8 Australians (2.87 million people) were
estimated to be providing informal care with each carer
providing up to 9 h per week in informal care. In the
absence of any data related to the number of carers’ for
skin cancer patients, carer costs were excluded.
Strengths
A strength of the analysis is the use of linked epidemio-
logical data. Data linkage transforms routinely collected
administrative data into a powerful resource for re-
search. For the current study, the linking of administra-
tive data provided a rich source of complementary
information on: diagnosis of melanoma (CCR); costs as-
sociated with skin cancer (MBS, PBS and the APDC);
and skin cancer mortality (CCR, APDC). Second, maxi-
mising the utility of the linked data set required a flex-
ible data analysis that was logical and robust. The
linkage process followed a sequential strategy that aimed
to minimise the number of false positive records. The
diagnosis criteria for melanoma and NMSC were informed
using relevant international classification of disease coding.
The statistical approach enabled a comprehensive and
rigorous assessment of the lifetime costs of skin cancer in
NSW. The costing approach was broadly consistent with
other studies analysing Medicare-linked population-based
databases in the United States [15–18, 52]. Third, consist-
ent with other costing studies, our analysis has attempted
Table 5 Summary of skin cancer costing studies, Australia, England, Sweden and New Zealand












Morris England 2002 UK pounds
Melanoma 6062 £24 £114 £138 £22,835 $67,537
NMSC 50,394 £97 £5 £101 £2014 $5955
Skin
cancer
56,456 £121 £119 £240 £4249 $12,567
Tinghog Sweden 2005 Euros
Melanoma 2122 € 22 € 58 € 80 € 37,545 $66,738
NMSC 36,262 € 31 € 5 € 36 € 998 $1775
Skin
cancer





Melanoma 1982 $6 $59 $65 $32,795 $30,326
NMSC 67,000 $51 $7 $58 $867 $802
Skin
cancer
68,982 $57 $66 $123 $1785 $1650
AIHW Australia 1993-94 AUD
Melanoma 6954 $66 $66 $9433 $14,805
NMSC 243,691 $232 $232 $953 $1496
Skin
cancer
250,645 $298 $298 $1189 $1865
AIHW Australia 2000-01 AUD
Melanoma 8885 $30 $30 $3376 $4561
NMSC 364,140 $264 $264 $725 $979
Skin
cancer
373,025 $294 $294 $788 $1065
Source: Morris et al. (2009) [31], Tinghog et al. (2008) [29], O’Dea (2009) [30]
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to place a monetary value on indirect costs [27–29, 53].
Our analysis only considers the economic value of pro-
ductive years of life lost is a conservative estimate of
mortality. Other studies quantify the economic value of
all years of life lost, not just that before the age of
65 years [28].
Comparability with other studies
In spite of methodological differences, the estimated
cost of skin cancer in NSW is generally consistent with
previous Australian and International studies (Table 5)
[29–31, 54, 55]. Compared with our estimate of the aver-
age cost per incident case of melanoma (AUD$44,796),
the English study calculated AUD$67,567 [31], the Swed-
ish study AUD$66,738 [29], and the New Zealand study
AUD$30,326 [30]. Compared with our estimate of the
average cost per incident case of NMSC (AUD$2459), the
English study calculated AUD$5955 [31], the Swedish
study AUD$1775 [29], and the New Zealand study
AUD$802 [30].
Previous estimates for the cost of skin cancer in
Australia only valued direct costs. Compared with our
estimate of the average direct cost per incident case of
melanoma (AUD$10,230), other Australian estimates
ranged from AUD$14,805 in a 1993–94 study [55] to
AUD$4561 in a 2000–01 study [54]. Compared with
our estimate of the average direct cost per incident case
NMSC (AUD$2336), other Australian estimates ranged
from AUD$1496 for the 1993–94 study [55] and
AUD$979 for the 2000–01 study [54].
Conclusion
This study provides new evidence on the economic costs
associated with skin cancer in NSW, Australia. Although
this analysis is based on the latest epidemiological and
economic evidence, there are still large knowledge gaps
in understanding the wider impact of skin cancer on so-
ciety. This lack of data means that the study most likely
under-estimates the true cost of skin cancer in NSW.
A key factor underpinning the strategic plan of the
Cancer Institute NSW is the knowledge that both mel-
anoma and NMSC are highly preventable. The most
effective means of reducing risk of developing skin can-
cer is to avoid direct exposure to UVR during the time
of day when solar UVR levels are moderate to extreme.
As a consequence of this analysis, we are in a better pos-
ition to quantify the savings to society of reducing the
incidence of skin cancer through preventive strategies
such as sunscreen or mass media campaigns efforts.
These savings are likely to be significant given the aver-
age lifetime cost of skin cancer in NSW is AUD$44,796
per melanoma case and AUD$2459 per NMSC case.
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